Clinical Trials Browser

Thymoma × Sunitinib × 1 year × Clear all

NCT03463460 2026-03-23

Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer

Phase 2 Active not recruiting

Thymoma